Apeloa Pharmaceutical Co.,Ltd
000739.SZ · SHZ
Market closed19.65-1.35 (-6.43%)
Key statistics
Previous close21.00
Open20.55
Day high21.20
Day low19.47
52-week high21.50
52-week low14.71
Market cap22.76B
Volume35.78M
Average volume13.99M
P/E ratio27.50
Forward P/E—
EPS0.71
Dividend yield+2.98%
Market context
Why it moved
The available news sources do not contain relevant information directly linked to 000739.SZ; however, the stock likely declined sharply today due to broad sector selling pressure or negative company-specific developments weighing on investor sentiment.
What is happening
Recent company-specific developments and publisher coverage.
finance.biggo.com · March 19, 2026Apeloa's 2025 Revenue and Net Profit Both Decline; CDMO Business Emerges as Sole Bright Spot with Nearly 17% Growth Against the TrendContract Pharma · October 30, 2025Apeloa Pharmaceutical Passes 20th FDA InspectionGlobeNewswire · August 27, 2025Hengdian Group’s Apeloa Pharmaceutical uses Flow Chemistry for sustainable manufacturingGenerics and Biosimilars Initiative · April 22, 2022Five Chinese companies join UN’s MPP for Covid-19 medicines Mt Newswire · July 17, 2026Apeloa Pharmaceutical to Set Up 10 Million Yuan Joint Venture Mt Newswire · May 29, 2026Apeloa Pharmaceutical's Unit Gets EU Certificate for Amantadine Hydrochloride Mt Newswire · May 22, 2026Apeloa Pharmaceutical Gets US FDA Nod for Hypertension, Angina Treatment Mt Newswire · May 18, 2026Apeloa Pharmaceutical Subsidiary Gets China Approval for Antibiotic Mt Newswire · April 21, 2026Apeloa Pharmaceutical Q1 Profit Inches Up; Shares Rise 4% Mt Newswire · April 16, 2026Apeloa Pharmaceutical Gets China Nod for Cholesterol-Lowering Drug Mt Newswire · March 23, 2026Apeloa Pharmaceutical Gets European Suitability Certificate for Antipsychotic Mt Newswire · December 24, 2025Apeloa Pharmaceutical Gets Regulatory Nod for Antiviral Drug